BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 24053431)

  • 1. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.
    Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC
    BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
    Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
    Fuzio P; Ditonno P; Lucarelli G; Battaglia M; Bettocchi C; Senia T; Perlino E
    Int J Oncol; 2011 Nov; 39(5):1233-42. PubMed ID: 21785821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
    Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
    Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.
    Kadono Y; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Mizokami A; Asahi H; Kobashi K; Koshida K; Namiki M
    Anticancer Res; 2013 Mar; 33(3):1147-51. PubMed ID: 23482794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
    Nishiyama T; Tomita Y; Takahashi K
    Urology; 2004 May; 63(5):917-21. PubMed ID: 15134981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
    Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
    Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
    Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
    J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
    Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
    Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
    Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
    Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
    Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
    Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
    Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
    Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry.
    Sadetsky N; Greene K; Cooperberg MR; Hubbard A; Carroll PR; Satariano W
    Cancer; 2011 Oct; 117(19):4406-13. PubMed ID: 21412760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.